欢迎访问《微生物与感染》官方网站,今天是
综述

呼吸道合胞病毒疫苗及其抗体制剂的研究进展

  • 吴小英1 ,
  • 孟庆红2 ,
  • 姚开虎2 ,
  • 许红梅1 ,
  • 符州3
展开
  • 1. 重庆医科大学附属儿童医院感染科,重庆 400014; 2. 国家儿童医学中心/首都医科大学附属北京儿童医院/北京市儿科研究所微生物研究室/儿科学国家重点学科/教育部儿科重大疾病研究重点实验室,北京 100045; 3. 重庆医科大学附属儿童医院呼吸中心,重庆 400014

收稿日期: 2020-12-16

  网络出版日期: 2022-02-25

Research progress of respiratory syncytial virus vaccine and antibody preparations

  • WU Xiaoying1 ,
  • MENG Qinghong2 ,
  • YAO Kaihu2 ,
  • XU Hongmei1 ,
  • FU Zhou3
Expand
  • 1. Department of Infection, Children’s Hospital of Chongqing Medical University, Chongqing 400014, China; 2. Key Laboratory of Major Diseases in Children,Ministry of Education/National Key Discipline of Pediatrics(Capital Medical University)/Laboratory of Microbiology, Beijing Pediatric Research Institute/Beijing Children’s Hospital, Capital Medical University/National Center for Children’s Health, Beijing 100045, China; 3. Respiratory Center, Children’s Hospital of Chongqing Medical University, Chongqing 400014, China

Received date: 2020-12-16

  Online published: 2022-02-25

摘要

呼吸道合胞病毒(respiratory syncytial virus,RSV)感染是一个全球性的健康问题,目前临床上仍缺乏特异的治疗手段。接种疫苗主动免疫预防或使用抗体制剂被动免疫预防是避免重症感染和减少死亡的重要措施。针对不同的人群,须研制不同类型的RSV疫苗:减毒活疫苗对婴儿来说,可能是最佳选择;亚单位疫苗有引起增强型呼吸道疾病的风险,不适合RSV血清学阴性的婴幼儿接种,主要适用于老年人和孕妇。研发安全且有效的RSV疫苗难度大,虽然已有30余种RSV疫苗进入临床研究阶段,并显示出应用潜力,其中F纳米颗粒疫苗已率先进入III期临床试验,但在老年人和孕妇中未达预期效果。在RSV流行季节前,使用特异性抗体制剂也是预防高危人群严重RSV感染性疾病的有效手段。长效单克隆抗体MEDI8897比帕利珠单抗更具成本效益,已进入III期临床试验,且获得优先研发资格。多克隆免疫球蛋白RI-002已在免疫缺陷人群中显示出较好的预防效果,具有进一步研发的现实意义。本综述针对近年来RSV疫苗及其抗体的研究进展进行阐述,期望为RSV的预防提供参考。

本文引用格式

吴小英1 , 孟庆红2 , 姚开虎2 , 许红梅1 , 符州3 . 呼吸道合胞病毒疫苗及其抗体制剂的研究进展[J]. 微生物与感染, 2022 , 17(1) : 55 -64 . DOI: 10.3969/j.issn.1673-6184.2022.01.008

Abstract

Respiratory syncytial virus (RSV) infection is an important global health problem. There is lack of specific treatment methods in clinical practice. Active prevention by vaccination or passive prevention by using antibody preparations are important measures to avoid severe infections and reduce deaths. Different RSV vaccines need to be developed for different populations. There are four main types of RSV vaccines under development. Live attenuated vaccines may be most suitable for infants. Subunit vaccines have the risk of causing enhanced respiratory diseases and are not suitable for infants with negative RSV serum vaccination, but they are mainly suitable for the elderly and pregnant women. Ensuring safety and immunogenicity is an important issue that needs to be solved in the development of RSV vaccines. Although there are many challenges in the development of RSV vaccines, more than 30 RSV vaccines have entered the clinical research stage, showing potential for application. Among them, the F nanoparticle vaccine has taken the lead in entering phase III clinical trials, but it has not achieved the expected effect in the elderly and pregnant women. Before the RSV epidemic season, using specific antibody is also an effective means to prevent severe infection in high-risk groups. The long-acting monoclonal antibody MEDI8897, which is more cost-effective than palivizumab, has entered phase III clinical trials, and has got priority R&D qualification. Polyclonal immunoglobulin RI-002 has shown good preventive effects in immunodeficiency populations, and has practical significance for further research.
文章导航

/